Goldman Sachs’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-70,113
| Closed | -$238K | – | 5938 |
|
|
2018
Q3 | $238K | Sell |
70,113
-50,425
| -42% | -$182K | ﹤0.01% | 4825 |
|
|
2018
Q2 | $453K | Sell |
120,538
-723,460
| -86% | -$3.52M | ﹤0.01% | 4567 |
|
|
2018
Q1 | $3.45M | Buy |
843,998
+154,575
| +22% | +$720K | ﹤0.01% | 3188 |
|
|
2017
Q4 | $3.21M | Sell |
689,423
-18,630
| -3% | -$103K | ﹤0.01% | 3388 |
|
|
2017
Q3 | $5.03M | Buy |
708,053
+22,380
| +3% | +$161K | ﹤0.01% | 3136 |
|
|
2017
Q2 | $4.96M | Buy |
685,673
+7,211
| +1% | +$45.1K | ﹤0.01% | 3064 |
|
|
2017
Q1 | $4.18M | Buy |
678,462
+22,388
| +3% | +$123K | ﹤0.01% | 3093 |
|
|
2016
Q4 | $3.85M | Buy |
656,074
+37,554
| +6% | +$205K | ﹤0.01% | 3280 |
|
|
2016
Q3 | $3.28M | Buy |
618,520
+186,758
| +43% | +$1.01M | ﹤0.01% | 3399 |
|
|
2016
Q2 | $2.86M | Buy |
431,762
+361,929
| +518% | +$2.02M | ﹤0.01% | 3314 |
|
|
2016
Q1 | $326K | Buy |
69,833
+3,362
| +5% | +$13.4K | ﹤0.01% | 5191 |
|
|
2015
Q4 | $336K | Sell |
66,471
-1,079,058
| -94% | -$5.13M | ﹤0.01% | 5266 |
|
|
2015
Q3 | $4.03M | Buy |
1,145,529
+1,027,323
| +869% | +$6.88M | ﹤0.01% | 3073 |
|
|
2015
Q2 | $1.18M | Buy |
118,206
+83,068
| +236% | +$891K | ﹤0.01% | 4387 |
|
|
2015
Q1 | $447K | Sell |
35,138
-29,647
| -46% | -$381K | ﹤0.01% | 5252 |
|
|
2014
Q4 | $917K | Sell |
64,785
-101,011
| -61% | -$1.57M | ﹤0.01% | 4660 |
|
|
2014
Q3 | $2.28M | Buy |
165,796
+2,201
| +1% | +$33.7K | ﹤0.01% | 3816 |
|
|
2014
Q2 | $2.52M | Buy |
163,595
+112,360
| +219% | +$1.59M | ﹤0.01% | 3758 |
|
|
2014
Q1 | $873K | Sell |
51,235
-514,373
| -91% | -$7.76M | ﹤0.01% | 4812 |
|
|
2013
Q4 | $7.33M | Sell |
565,608
-200,950
| -26% | -$2.4M | ﹤0.01% | 2657 |
|
|
2013
Q3 | $7.74M | Buy |
766,558
+231,868
| +43% | +$2.06M | ﹤0.01% | 2505 |
|
|
2013
Q2 | $3.99M | Buy |
+534,690
| New | +$4.18M | ﹤0.01% | 2974 |
|
Goldman Sachs's KERX Position: Q4 2018 in Review
Goldman Sachs sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 70,113 shares — an estimated $238K sold.
Goldman Sachs first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $7.74M in Q3 2013. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Goldman Sachs reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Goldman Sachs sold 70,113 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $238K.
- Goldman Sachs first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Goldman Sachs's Keryx Biopharmaceuticals Inc position peaked at $7.74M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.